Beam Therapeutics Inc (BEAM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.36B
Last updated: Nov 17, 2026 at 11:05 AM ET
Beam Therapeutics Inc (BEAM) Earnings: Report Dates and Results
Beam Therapeutics (BEAM) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Beam Therapeutics reported EPS of -$1.28, below the -$1.17 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BEAM has an expected report date of Feb 22, 2027.
BEAM Earnings Call
The latest BEAM earnings call transcript on file is labeled 2025Q4.
Read the 2025Q4 transcriptEarnings History
Of the 28 quarters below that had an estimate, BEAM beat 14, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $307000, down 96.8% from $9.70M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.28 | -$1.17 | -$1.28 - -$1.05 | -9.40% | Miss | N/A | 13 | 4 up, 5 down | Nov 3, 2026 | $307000 |
| Jun 30, 2026 | -$1.18 | $1.00 | N/A | -218.00% | Miss | N/A | 12 | 2 up, 8 down | Aug 4, 2026 | $490000 |
| Mar 31, 2026 | -$0.91 | -$1.01 | -$1.19 - -$0.08 | +9.90% | Beat | N/A | 13 | 6 up, 1 down | May 7, 2026 | $31.74M |
| Dec 31, 2025 | $2.33 | -$1.01 | -$1.28 - -$0.90 | +330.69% | Beat | N/A | 13 | 1 up, 7 down | Feb 24, 2026 | $114.11M |
| Sep 30, 2025 | -$1.10 | -$1.01 | -$1.16 - -$0.79 | -8.91% | Miss | N/A | 12 | 0 up, 0 down | Nov 4, 2025 | $9.70M |
| Jun 30, 2025 | -$1.00 | -$1.09 | -$1.40 - -$0.78 | +8.26% | Beat | N/A | 14 | 0 up, 1 down | Aug 5, 2025 | $8.47M |
| Mar 31, 2025 | -$1.24 | -$1.17 | -$1.47 - -$0.70 | -5.98% | Miss | N/A | 14 | 1 up, 4 down | May 6, 2025 | $7.47M |
| Dec 31, 2024 | -$1.09 | -$1.22 | -$1.59 - -$0.88 | +10.35% | Beat | -163.0% | 16 | 2 up, 0 down | Feb 25, 2025 | $30.07M |
| Sep 30, 2024 | -$1.17 | -$1.18 | -$1.35 - -$0.94 | +0.85% | Beat | N/A | 16 | 0 up, 0 down | Nov 5, 2024 | $14.27M |
| Jun 30, 2024 | -$1.11 | -$1.12 | -$1.33 - -$0.91 | +0.89% | Beat | N/A | 14 | 0 up, 0 down | Aug 6, 2024 | $11.77M |
| Mar 31, 2024 | -$1.21 | -$1.39 | -$2.16 - -$1.18 | +12.95% | Beat | N/A | 12 | 0 up, 0 down | May 7, 2024 | $7.41M |
| Dec 31, 2023 | $1.73 | -$1.01 | -$1.46 - $1.21 | +271.29% | Beat | N/A | 12 | 1 up, 0 down | Feb 27, 2024 | $316.19M |
| Sep 30, 2023 | -$1.22 | -$1.27 | -$1.62 - -$1.19 | +3.94% | Beat | N/A | 13 | 1 up, 1 down | Nov 8, 2023 | $17.19M |
| Jun 30, 2023 | -$1.08 | -$1.38 | -$1.73 - -$1.15 | +21.74% | Beat | N/A | 13 | 0 up, 0 down | Aug 8, 2023 | $20.12M |
| Mar 31, 2023 | -$1.33 | -$1.30 | -$1.61 - -$1.12 | -2.31% | Miss | N/A | 13 | 0 up, 0 down | May 10, 2023 | $24.21M |
| Dec 31, 2022 | -$0.54 | -$1.33 | -$1.85 - -$0.79 | +59.40% | Beat | N/A | 14 | 0 up, 0 down | Feb 28, 2023 | $20.04M |
| Sep 30, 2022 | -$1.56 | -$1.09 | N/A | -43.12% | Miss | N/A | 12 | 0 up, 0 down | Nov 7, 2022 | $15.80M |
| Jun 30, 2022 | -$1.02 | -$1.02 | -$1.28 - -$0.85 | 0.00% | In line | N/A | 11 | 0 up, 0 down | Aug 9, 2022 | $16.65M |
| Mar 31, 2022 | -$1.01 | -$1.34 | N/A | +24.63% | Beat | N/A | N/A | N/A | May 9, 2022 | $8.43M |
| Dec 31, 2021 | -$0.95 | -$1.03 | N/A | +7.77% | Beat | N/A | N/A | N/A | Feb 28, 2022 | $51.07M |
| Sep 30, 2021 | -$0.42 | -$0.72 | N/A | +41.67% | Beat | N/A | N/A | N/A | Nov 8, 2021 | $763000 |
| Jun 30, 2021 | -$1.23 | -$0.74 | N/A | -66.22% | Miss | N/A | N/A | N/A | Aug 10, 2021 | $6000 |
| Mar 31, 2021 | -$3.35 | -$0.75 | N/A | -346.67% | Miss | N/A | N/A | N/A | May 11, 2021 | $6000 |
| Dec 31, 2020 | -$1.69 | -$0.67 | N/A | -152.24% | Miss | N/A | N/A | N/A | Mar 15, 2021 | $6000 |
| Sep 30, 2020 | -$0.69 | -$0.54 | N/A | -27.78% | Miss | N/A | N/A | N/A | Nov 10, 2020 | $6000 |
| Jun 30, 2020 | -$0.69 | -$0.51 | N/A | -35.29% | Miss | N/A | N/A | N/A | Aug 12, 2020 | $6000 |
| Mar 31, 2020 | -$1.03 | -$0.48 | N/A | -114.58% | Miss | N/A | N/A | N/A | May 12, 2020 | $6000 |
| Dec 31, 2019 | -$4.47 | -$0.52 | N/A | -759.62% | Miss | N/A | N/A | N/A | Feb 7, 2020 | $6000 |
| Sep 30, 2019 | -$1.44 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 27, 2019 | $6000 |
| Jun 30, 2019 | -$0.45 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 27, 2019 | $6000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.01, after -$4.58 the year before. It was -$6.36 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.01 | N/A |
| Dec 31, 2024 | -$4.58 | N/A |
| Dec 31, 2023 | -$1.90 | N/A |
| Dec 31, 2022 | -$4.13 | N/A |
| Dec 31, 2021 | -$5.95 | N/A |
| Dec 31, 2020 | -$4.10 | N/A |
| Dec 31, 2019 | -$6.36 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 9,300 words across 21 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q4 | Dec 31, 2025 | 9,331 | 21 | |
| 2024Q3 | Sep 30, 2024 | 5,779 | 16 |
2025Q4 Earnings Call
Opening remarks
Holly Manning Vice President of Investor Relations and External Communications Thank you, operator. Good morning, everyone, and welcome to Beam's Conference Call to review updates announced this morning in conjunction with our fourth quarter and year-end 2025 financial results. You can access slides for today's call by going to the Investors section of our website, beamtx.com. With me on the call today, with prepared remarks, are John Evans, our Chief Executive Officer; Dr. Amy Simon, our Chief Medical Officer; Dr. Gopi Shanker, our Chief Scientific Officer; Sravan Emany, our Chief Financial Officer; and Dr. Kiran Musunuru from the University of Pennsylvania. Our President, Dr. Guiseppe Pino Ciaramella, will join for Q&A. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the Risk Factors section of our most recent annual report on Form 10-K and any other filings that we may make with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, Beam specifically disclaims any obligation to update or revise any forward-looking statements even if our views change. With that, I'll turn the call over to John.
John Evans CEO Thanks, Holly, and good morning, everyone. At Beam, our vision is straightforward, but ambitious: to provide lifelong cures for patients suffering from serious diseases. We believe base editing has the potential to deliver on that vision through onetime durable genetic medicines with predictable and reproducible outcomes. Today, we're excited to share several important updates that bring us closer to accomplishing this mission. First, leveraging our platform to bring forward a new and innovative development program to address a serious genetic disease, phenylketonuria, or PKU, and second, further solidifying our balance sheet to support the anticipated commercialization of a potentially transformative onetime base editing therapy for sickle cell disease. Beam was founded on a simple concept: aimed at rewriting broken genes back to normal. Base editing is a next-generation form of CRISPR that allows us to make precise single-base changes, resulting in predictable edits without the need to make double-stranded breaks in DNA. With consistent gene sequence outcomes conferring potentially lifelong benefit, base editing enables predictable, reproducible outcomes for patients. This scientific foundation underpins everything we do. Predictability is a theme you'll hear throughout today's discussion.
Frequently Asked Questions About BEAM
When is Beam Therapeutics's next earnings date?
Beam Therapeutics's next earnings report is expected for Feb 22, 2027.
Did BEAM beat earnings estimates last quarter?
No. Beam Therapeutics reported EPS of -$1.28 for the quarter ended Sep 30, 2026, below the -$1.17 estimate by 9.40%.
What EPS do analysts expect from BEAM next quarter?
The consensus EPS estimate for Beam Therapeutics for the quarter ending Dec 31, 2026 is -$1.25 from 17 analysts, with estimates from -$1.32 to -$1.19.
How often does BEAM beat earnings estimates?
Beam Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +14.61%.
BEAM pages: Overview, Earnings, Forecast, Financials, Competitors